Next-Generation Endocrine Therapies for Breast Cancer.
作者信息
McDonnell Donald P, Wardell Suzanne E, Chang Ching-Yi, Norris John D
机构信息
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC.
出版信息
J Clin Oncol. 2021 Apr 20;39(12):1383-1388. doi: 10.1200/JCO.20.03565. Epub 2021 Mar 11.
Abstract
摘要
相似文献
1
Next-Generation Endocrine Therapies for Breast Cancer.乳腺癌的新一代内分泌治疗方法
J Clin Oncol. 2021 Apr 20;39(12):1383-1388. doi: 10.1200/JCO.20.03565. Epub 2021 Mar 11.
2
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.选择性雌激素受体调节剂和下调剂的临床应用，主要聚焦于乳腺癌。
Minerva Ginecol. 2009 Dec;61(6):517-39.
3
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.选择性雌激素受体调节剂在乳腺癌和子宫内膜癌治疗中的综述。
Semin Oncol. 2002 Jun;29(3 Suppl 11):129-33. doi: 10.1053/sonc.2002.34065.
4
[Future endocrine therapy of breast cancer].[乳腺癌的未来内分泌治疗]
Ugeskr Laeger. 2007 Jan 22;169(4):296.
5
Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.雌激素受体-β在预测老年乳腺癌患者新辅助抗雌激素治疗反应中的前瞻性评估
Endocr Relat Cancer. 2004 Dec;11(4):761-70. doi: 10.1677/erc.1.00822.
6
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.选择性雌激素受体调节剂和选择性雌激素受体下调剂在乳腺癌中的应用。
Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. doi: 10.1016/j.beem.2003.08.002.
7
[Advancement in endocrine therapy for breast cancer].[乳腺癌内分泌治疗的进展]
Ai Zheng. 2007 Apr;26(4):440-4.
8
Endocrine resistance in breast cancer.乳腺癌中的内分泌耐药性。
Climacteric. 2014 Oct;17(5):522-8. doi: 10.3109/13697137.2013.864268. Epub 2013 Dec 19.
9
[Antiestrogenic agents for treatment of advanced breast cancers].[用于治疗晚期乳腺癌的抗雌激素药物]
Nihon Rinsho. 2000 Apr;58 Suppl:311-6.
10
Estrogen receptor mutations and their role in breast cancer progression.雌激素受体突变及其在乳腺癌进展中的作用。
Breast Cancer Res. 2014 Dec 12;16(6):494. doi: 10.1186/s13058-014-0494-7.
引用本文的文献
1
PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ERHER2 breast cancer harbouring acquired ESR1 mutations.PROTAC SERD药物维迪西妥昔单抗在携带获得性ESR1突变的晚期ER⁺HER2⁻乳腺癌中表现优于氟维司群。
Nat Rev Clin Oncol. 2025 Jul 22. doi: 10.1038/s41571-025-01062-6.
2
Sex bias in tumor immunity: insights from immune cells.肿瘤免疫中的性别偏见：来自免疫细胞的见解
Theranostics. 2025 Mar 31;15(11):5045-5072. doi: 10.7150/thno.106465. eCollection 2025.
3
Breast cancer: pathogenesis and treatments.乳腺癌：发病机制与治疗方法
Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4.
4
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?雌激素受体与p53之间的相互作用：他莫昔芬的作用更广泛？
Endocrinology. 2025 Feb 5;166(3). doi: 10.1210/endocr/bqaf020.
5
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.Elacestrant用于雌激素受体阳性且人表皮生长因子受体2阴性的早期乳腺癌女性患者：术前机会窗ELIPSE试验结果
Clin Cancer Res. 2025 Apr 1;31(7):1223-1232. doi: 10.1158/1078-0432.CCR-24-2460.
6
The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.用于乳腺癌内分泌治疗反应与耐药性的EstroGene2.0数据库。
NPJ Breast Cancer. 2024 Dec 19;10(1):106. doi: 10.1038/s41523-024-00709-4.
7
Antioxidant 1,2,3,4,6-Penta--galloyl-β-D-glucose Alleviating Apoptosis and Promoting Bone Formation Is Associated with Estrogen Receptors.抗氧化剂 1,2,3,4,6-五没食子酰基-β-D-葡萄糖通过雌激素受体减轻细胞凋亡并促进骨形成。
Molecules. 2024 Oct 29;29(21):5110. doi: 10.3390/molecules29215110.
8
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth.雌激素信号抑制肿瘤相关组织嗜酸性粒细胞浸润，促进乳腺癌生长。
Sci Adv. 2024 Sep 27;10(39):eadp2442. doi: 10.1126/sciadv.adp2442.
9
EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer.EstroGene2.0：一个关于乳腺癌对雌激素、雌激素受体调节剂的反应以及内分泌治疗耐药性的多组学数据库。
bioRxiv. 2024 Jul 2:2024.06.28.601163. doi: 10.1101/2024.06.28.601163.
10
Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression.铜掺杂碳量子点对乳腺癌进展的抗癌效力
Int J Nanomedicine. 2024 Feb 27;19:1985-2004. doi: 10.2147/IJN.S449887. eCollection 2024.
本文引用的文献
1
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Elacestrant（RAD1901），一种新型选择性雌激素受体降解剂，在 ER 阳性、HER2 阴性晚期乳腺癌中的 I 期研究。
J Clin Oncol. 2021 Apr 20;39(12):1360-1370. doi: 10.1200/JCO.20.02272. Epub 2021 Jan 29.
2
The Dysregulated Pharmacology of Clinically Relevant Mutants is Normalized by Ligand-activated WT Receptor.临床上相关突变体的药理学失调可通过配体激活的 WT 受体来正常化。
Mol Cancer Ther. 2020 Jul;19(7):1395-1405. doi: 10.1158/1535-7163.MCT-19-1148. Epub 2020 May 7.
3
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.Elacestrant（RAD1901）在多种对 CDK4/6 抑制剂耐药的 ER+ 乳腺癌模型中表现出抗肿瘤活性。
Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0.
4
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
5
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.妇科恶性肿瘤中组成性激活的 ESR1 突变与雌激素受体靶向治疗的临床反应。
Gynecol Oncol. 2019 Jul;154(1):199-206. doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13.
6
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα and ERα Breast Cancer.选择性雌激素受体共价拮抗剂的发现用于 ERα 和 ERα 乳腺癌的治疗。
Cancer Discov. 2018 Sep;8(9):1176-1193. doi: 10.1158/2159-8290.CD-17-1229. Epub 2018 Jul 10.
7
On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases.论乳癌不可手术病例的治疗：一种新治疗方法的建议及实例说明
Trans Med Chir Soc Edinb. 1896;15:153-179.
8
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.ESR1 激活突变的等位基因特异性染色质募集和治疗弱点。
Cancer Cell. 2018 Feb 12;33(2):173-186.e5. doi: 10.1016/j.ccell.2018.01.004.
9
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.选择性雌激素受体调节剂（SERMs）和选择性雌激素受体降解剂（SERDs）在癌症治疗中的应用。
Pharmacol Ther. 2018 Jun;186:1-24. doi: 10.1016/j.pharmthera.2017.12.012. Epub 2017 Dec 28.
10
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.绝经激素治疗与全因及特定病因长期死亡率：妇女健康倡议随机试验
JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217.
Zotero 插件